Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage precision oncology company, and its news flow reflects the progress and risks of early-stage cancer drug development. Company announcements frequently cover updates on highly selective SMARCA2 degraders, oral KAT6A degraders, a mutant selective JAK2V617F JH2 inhibitor program for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Investors and researchers following PRLD news can expect regular reports on clinical trial milestones, such as Phase 1 dose-escalation progress for PRT7732, completion of Phase 1 studies for PRT3789, and plans for Phase 2 combinations with agents like pembrolizumab. Press releases also summarize preclinical data presented at major medical meetings, including the American Association for Cancer Research, the American Society of Hematology, European Hematology Association, and other oncology-focused conferences.
Prelude’s news often highlights strategic portfolio decisions, for example prioritizing KAT6A and JAK2V617F programs, pausing further clinical development of certain SMARCA2 programs, and expanding collaborations. Announcements have detailed an exclusive option agreement with Incyte for the JAK2V617F program and an expanded collaboration with AbCellera Biologics around degrader payloads for precision DACs.
In addition, PRLD news includes quarterly financial results, cash runway commentary, and governance updates such as board appointments and leadership changes. For those tracking precision oncology and targeted protein degradation, this news stream provides insight into Prelude’s evolving pipeline, partnership activity, and regulatory and listing developments. Bookmark this page to review the latest earnings releases, scientific data disclosures, and corporate updates related to Prelude Therapeutics stock.
Prelude Therapeutics (Nasdaq: PRLD) has announced its participation in the upcoming Citizens JMP Securities Hematology and Oncology Summit, scheduled for December 2, 2024. The virtual event will feature a fireside chat at 11:30 a.m. ET with CEO Kris Vaddi, Ph.D., and President/CMO Jane Huang, M.D. The session will be available via webcast on the company's website and archived for 90 days.
Prelude Therapeutics specializes in precision oncology, developing innovative medicines for high-unmet cancer patient needs. Their pipeline includes first-in-class SMARCA2 degraders (both IV and oral) and a CDK9 inhibitor. The company is also advancing Precision ADCs through partnerships.
Prelude Therapeutics (PRLD) reported Q3 2024 financial results and clinical updates. Key highlights include interim data from Phase 1 study of PRT3789, showing clinical proof of concept in SMARCA4-mutated cancers. The company initiated Phase 1 trial for PRT7732 and presented preclinical data from its Precision ADC platform. Financial position remains strong with $153.6M cash runway into 2026. Q3 net loss was $32.3M ($0.43/share). R&D expenses increased to $29.5M from $26.3M year-over-year, while G&A expenses rose to $7.9M from $7.1M.
Prelude Therapeutics presented interim data from its ongoing Phase 1 trial of PRT3789, a SMARCA2 degrader for cancer patients with SMARCA4 mutations. Of 65 patients treated, the drug showed promising results with 4 confirmed partial responses among 26 evaluable NSCLC or esophageal patients with Class 1 mutations. Higher doses demonstrated deeper SMARCA2 degradation, with 2 of 9 NSCLC patients showing confirmed responses at doses of 283mg or higher.
The drug was generally well-tolerated, with mostly mild to moderate adverse events. Initial combination study with docetaxel showed an acceptable safety profile. The company also presented first preclinical proof-of-concept data from their novel SMARCA2/4 dual degrader payload program.
Prelude Therapeutics (Nasdaq: PRLD) announced the publication of three abstracts for presentation at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain from October 23-25, 2024. The abstracts focus on the company's SMARCA Degrader Programs, including:
1. First clinical results from a Phase 1 trial of PRT3789, a first-in-class SMARCA2 degrader, in patients with advanced solid tumors with SMARCA4 mutations.
2. Discovery of first-in-class precision antibody drug conjugates with a potent SMARCA 2/4 dual degrader payload.
3. The selective SMARCA2 degrader, PRT3789, enhancing the efficacy of standard chemotherapy in SMARCA4 mutant NSCLC models.
Prelude expects to conclude monotherapy dose escalation for PRT3789 by year-end 2024 and identify the biologically active dose for future trials. The company is also enrolling patients in back-fill cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations at higher dose levels.
Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activity in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
- 3 confirmed partial responses observed
- 7 out of 26 evaluable NSCLC or esophageal patients showed tumor shrinkage
- Generally well-tolerated safety profile with no dose-limiting toxicities
- Dose escalation continuing to 9th cohort (500mg once weekly)
The company plans to confirm the biologically active dose for PRT3789 monotherapy by year-end and advance combination studies with docetaxel. These results represent initial proof of concept for selective SMARCA2 degradation in certain SMARCA4 mutated cancers.
Prelude Therapeutics (Nasdaq: PRLD) has announced the publication of an abstract for their novel SMARCA2 degrader, PRT3789, to be presented at the ESMO Congress 2024. The presentation will showcase the first clinical data for this highly-selective compound in patients with advanced solid tumors harboring SMARCA4 mutations.
Key points from the abstract include:
- 40 patients enrolled across various cancer types
- No dose-limiting toxicities or drug-related serious adverse events reported
- Dose-dependent decreases in SMARCA2 levels observed
- Clinical activity noted, including partial responses and tumor shrinkage
Prelude will host an investor webcast on September 13, 2024, to discuss the updated data presented at ESMO.
Prelude Therapeutics (NASDAQ: PRLD) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
- Interim Phase 1 data for PRT3789, a first-in-class IV SMARCA2 degrader, selected for oral presentation at ESMO 2024
- Received FDA IND authorization for PRT7732, a first-in-class oral SMARCA2 degrader
- Announced clinical collaboration with Merck to evaluate PRT3789 with KEYTRUDA in SMARCA4-mutated cancers
- CDK9 inhibitor PRT2527 on track to report interim Phase 1 data in Q4 2024
- Cash runway into 2026 with $179.8 million as of June 30, 2024
Q2 2024 financials: R&D expenses increased to $29.5 million, G&A expenses rose to $7.7 million, and net loss was $34.7 million ($0.46 per share).
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential of this combination to enhance anti-tumor activity due to the complementary mechanisms of the two treatments. Prelude will sponsor the trial, while Merck will supply KEYTRUDA. PRT3789 is in Phase 1 development for SMARCA4 mutant patients, with dose escalation expected to conclude mid-2024. Early pre-clinical data indicated promising anti-tumor immunity and tumor regression when combining SMARCA2 degraders with anti-PD-1 therapies. Both companies retain commercial rights to their respective treatments.
Prelude Therapeutics, a clinical-stage precision oncology company, announced its participation in two notable healthcare conferences this June. CEO Kris Vaddi will engage in a fireside chat at the Jefferies Global Healthcare Conference on June 6th at 1:30 p.m. ET. Additionally, Dr. Vaddi will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12th at 10:40 a.m. ET. Both events will be webcast live and archived on the company's website for 90 days.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) will participate in the Citizens JMP Life Sciences Conference in New York City on May 13 and 14. The Company's CEO and Chief Medical Officer will engage in a fireside chat, with a live webcast accessible on their website. The event aims to showcase the company's developments in precision oncology.